Guidelines for standardizing T‐cell cytometry assays to link biomarkers, mechanisms, and disease outcomes in type 1 diabetes. Issue 3 (28th January 2022)

• Record Type: Journal Article
• Authors: Yang, Jennie H. M.; Ward‐Hartstonge, Kirsten A.; Perry, Daniel J.; Blanchfield, J. Lori; Posgai, Amanda L.; Wiedeman, Alice E.; Diggins, Kirsten; Rahman, Adeeb; Tree, Timothy I. M.; Brusko, Todd M.; Levings, Megan K.; James, Eddie A.; Kent, Sally C.; Speake, Cate; Homann, Dirk; Long, S. Alice
• Is Part Of: European journal of immunology. Volume 52:Issue 3(2022)
• Page Start: 372
• Page End: 388
• Publication Date: 2022-01-28
• Subjects: type 1 diabetes -- flow cytometry -- immune monitoring -- biomarkers -- T cells; Immunology -- Periodicals; 616.079
• DOI: 10.1002/eji.202049067
• Languages: English
• ISSNs: 0014-2980

Abstract

Abstract: Cytometric immunophenotyping is a powerful tool to discover and implement T‐cell biomarkers of type 1 diabetes (T1D) progression and response to clinical therapy. Although many discovery‐based T‐cell biomarkers have been described, to date, no such markers have been widely adopted in standard practice. The heterogeneous nature of T1D and lack of standardized assays and experimental design across studies is a major barrier to the broader adoption of T‐cell immunophenotyping assays. There is an unmet need to harmonize the design of immunophenotyping assays, including those that measure antigen‐agnostic cell populations, such that data collected from different clinical trial sites and T1D cohorts are comparable, yet account for cohort‐specific features and different drug mechanisms of action. In these Guidelines, we aim to provide expert advice on how to unify aspects of study design and practice. We provide recommendations for defining cohorts, method implementation, as well as tools for data analysis and reporting by highlighting and building on selected successes. Harmonization of cytometry‐based T‐cell assays will allow researchers to better integrate findings across trials, ultimately enabling the identification and validation of biomarkers of disease progression and treatment response in T1D. Abstract : There are many biomarkers of response to therapies for type 1 diabetes, but few have been widely adopted. Focusing on immunophenotyping, we discuss approaches to standardize and harmonize various aspects of biomarker measurement. Following these guidelines, we will allow biomarker integration across trials and validation of their clinical utility.